First Response now has a pregnancy test tied to a health app that helps users manage their stress as it monitors hormone levels. What next?
These are the states with the leading programs based on quality controls, patient safety and civil protections, according to ASA Foundation.
Demand for home medical devices is booming. Innovations keep rolling out — from smart baby monitors to infrared thermometers.
Ex Apple and Pepsi CEO wants to transform the"antiquated" health care industry
Biotech CEOs say that drug pricing needs to be balanced enough to support research and development.
Ipsita Smolinksi, Capitol Street; Dr. Ron Cohen, Acorda; and Dr. Peter Bach, Memorial Sloan Kettering Center for Health Policy,discuss rising drug prices and affordable care for patients.
Dr. Flemming Ornskov, Shire PLC CEO, discusses rare diseases and the economics behind his deal with Baxalta.
CNBC's Meg Tirrell sits down with Dr. Flemming Ornskov, Shire PLC CEO, to discuss Shire's deal with Baxalta worth $32 billion.
Bristol-Myers Squibb CEO Dr. Giovanni Caforio, provides insight to his company's position in the biotech industry, and the thinking about pricing in cancer drugs.
BioMarin CEO Jean-Jacques Bienaime, discusses drug pricing, the sentiment of investors in biotech and his expectations for the company's Duchenne muscular dystrophy drug.
Checking on the biotech industry, and the outlook for ARIAD Pharmaceuticals, with Alex Denner, Sarissa Capital Management founder and CIO.
GlaxoSmithKline CEO Sir Andrew Witty says he expects growth in his firm's three major businesses.
Regeneron CEO Len Schleifer says drug pricing needs to be balanced enough to support research and development.
Samuel Waksal, Kadmon Corporation founder, shares his thesis on pricing in the pharmaceutical industry.
This company promises to detect cancer early by performing liquid biopsies.
While the biotech sector has been under fire for high drug prices, Biotech CEO says that it brings innovations.
CNBC's Meg Tirrell sits down with Kenneth Frazier, Merck Chairman & CEO, to discuss what investors should expect from Merck and the company's competitive regimen.
Illumina CEO Jay Flatley explains the technology behind new technology allowing for cancer screening using blood tests.
Biogen CEO George Scangos discusses research and development in biotech and the impact of mounting drug pricing pressures.
Biogen CEO George Scangos weighs in on the effect of an underperfoming market on M&A in biotech.
By 2019, the number of people without insurance would be nearly 59 million, with an uninsured rate of 21 percent, a new analysis says.
The nation's health insurers on Tuesday publicly outlined for the first time what the industry wants to stay in the state marketplaces. NYT reports.
Health-care stocks haven't gotten the green light many expected from Hillary Clinton's election loss.
Take an in-depth look at the world of modern medicine - examining the treatments, companies and people making a difference in the way we treat illness and injuries today, and laying the foundation for the medical treatments of tomorrow.
THE PULSE is a look at technology’s impact on our daily lives and how it will affect us in the future.
The buzz on the trading floor